Steroid-free living donor liver transplantation for HCV - a multicenter prospective cohort study in Japan

Shigeru Marubashi, Koji Umeshita, Toshimasa Asahara, Kenji Fujiwara, Hironori Haga, Takashi Hashimoto, Katsuyoshi Hatakeyama, Takafumi Ichida, Takashi Kanematsu, Masaki Kitajima, Kendo Kiyosawa, Masatoshi Makuuchi, Shinichi Miyagawa, Susumu Satomi, Yuji Soejima, Yasutsugu Takada, Noriaki Tanaka, Satoshi Teraoka, Morito Monden

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

This prospective, non-randomized, multicenter cohort study analyzed the safety and efficacy of a steroid-free immunosuppressive (IS) protocol for hepatitis C virus (HCV)-positive living donor liver transplant (LDLT) recipients in Japan. Of 68 patients enrolled from 13 transplant centers, 56 fulfilled the inclusion/exclusion criteria; 27 were assigned the steroid-free IS protocol (Fr group) and 29 the traditional steroid-containing IS protocol (St group). Serum HCV RNA levels increased over time and were higher in the St group until postoperative day 90 (POD 14, p = 0.013). Preemptive anti-HCV therapy was started in a higher percentage of recipients (59.3%) in the Fr group than in the St group (31.0%, p = 0.031), mainly due to early HCV recurrence. The incidence of HCV recurrence at one yr was lower in the Fr group (22.2%) than in the St group (41.4%; p = 0.066). The incidence of acute cellular rejection was similar between groups. New onset diabetes after transplant, cytomegalovirus infection, and renal dysfunction were significantly less frequent in the Fr group than in the St group (p = 0.022, p < 0.0001, p = 0.012, respectively). The steroid-free IS protocol safely reduced postoperative morbidity and effectively suppressed both the HCV viral load in the early post-transplant period and HCV recurrence in HCV-positive LDLT recipients.

Original languageEnglish
Pages (from-to)857-867
Number of pages11
JournalClinical Transplantation
Volume26
Issue number6
DOIs
Publication statusPublished - Nov 1 2012

Fingerprint

Living Donors
Hepacivirus
Liver Transplantation
Japan
Cohort Studies
Steroids
Prospective Studies
Immunosuppressive Agents
Transplants
Recurrence
Liver
Incidence
Cytomegalovirus Infections
Viral Load
Multicenter Studies
RNA
Morbidity
Kidney
Safety
Serum

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Marubashi, S., Umeshita, K., Asahara, T., Fujiwara, K., Haga, H., Hashimoto, T., ... Monden, M. (2012). Steroid-free living donor liver transplantation for HCV - a multicenter prospective cohort study in Japan. Clinical Transplantation, 26(6), 857-867. https://doi.org/10.1111/j.1399-0012.2012.01627.x

Steroid-free living donor liver transplantation for HCV - a multicenter prospective cohort study in Japan. / Marubashi, Shigeru; Umeshita, Koji; Asahara, Toshimasa; Fujiwara, Kenji; Haga, Hironori; Hashimoto, Takashi; Hatakeyama, Katsuyoshi; Ichida, Takafumi; Kanematsu, Takashi; Kitajima, Masaki; Kiyosawa, Kendo; Makuuchi, Masatoshi; Miyagawa, Shinichi; Satomi, Susumu; Soejima, Yuji; Takada, Yasutsugu; Tanaka, Noriaki; Teraoka, Satoshi; Monden, Morito.

In: Clinical Transplantation, Vol. 26, No. 6, 01.11.2012, p. 857-867.

Research output: Contribution to journalArticle

Marubashi, S, Umeshita, K, Asahara, T, Fujiwara, K, Haga, H, Hashimoto, T, Hatakeyama, K, Ichida, T, Kanematsu, T, Kitajima, M, Kiyosawa, K, Makuuchi, M, Miyagawa, S, Satomi, S, Soejima, Y, Takada, Y, Tanaka, N, Teraoka, S & Monden, M 2012, 'Steroid-free living donor liver transplantation for HCV - a multicenter prospective cohort study in Japan', Clinical Transplantation, vol. 26, no. 6, pp. 857-867. https://doi.org/10.1111/j.1399-0012.2012.01627.x
Marubashi, Shigeru ; Umeshita, Koji ; Asahara, Toshimasa ; Fujiwara, Kenji ; Haga, Hironori ; Hashimoto, Takashi ; Hatakeyama, Katsuyoshi ; Ichida, Takafumi ; Kanematsu, Takashi ; Kitajima, Masaki ; Kiyosawa, Kendo ; Makuuchi, Masatoshi ; Miyagawa, Shinichi ; Satomi, Susumu ; Soejima, Yuji ; Takada, Yasutsugu ; Tanaka, Noriaki ; Teraoka, Satoshi ; Monden, Morito. / Steroid-free living donor liver transplantation for HCV - a multicenter prospective cohort study in Japan. In: Clinical Transplantation. 2012 ; Vol. 26, No. 6. pp. 857-867.
@article{1a95ce1beca94f9091aec8f7a4382217,
title = "Steroid-free living donor liver transplantation for HCV - a multicenter prospective cohort study in Japan",
abstract = "This prospective, non-randomized, multicenter cohort study analyzed the safety and efficacy of a steroid-free immunosuppressive (IS) protocol for hepatitis C virus (HCV)-positive living donor liver transplant (LDLT) recipients in Japan. Of 68 patients enrolled from 13 transplant centers, 56 fulfilled the inclusion/exclusion criteria; 27 were assigned the steroid-free IS protocol (Fr group) and 29 the traditional steroid-containing IS protocol (St group). Serum HCV RNA levels increased over time and were higher in the St group until postoperative day 90 (POD 14, p = 0.013). Preemptive anti-HCV therapy was started in a higher percentage of recipients (59.3{\%}) in the Fr group than in the St group (31.0{\%}, p = 0.031), mainly due to early HCV recurrence. The incidence of HCV recurrence at one yr was lower in the Fr group (22.2{\%}) than in the St group (41.4{\%}; p = 0.066). The incidence of acute cellular rejection was similar between groups. New onset diabetes after transplant, cytomegalovirus infection, and renal dysfunction were significantly less frequent in the Fr group than in the St group (p = 0.022, p < 0.0001, p = 0.012, respectively). The steroid-free IS protocol safely reduced postoperative morbidity and effectively suppressed both the HCV viral load in the early post-transplant period and HCV recurrence in HCV-positive LDLT recipients.",
author = "Shigeru Marubashi and Koji Umeshita and Toshimasa Asahara and Kenji Fujiwara and Hironori Haga and Takashi Hashimoto and Katsuyoshi Hatakeyama and Takafumi Ichida and Takashi Kanematsu and Masaki Kitajima and Kendo Kiyosawa and Masatoshi Makuuchi and Shinichi Miyagawa and Susumu Satomi and Yuji Soejima and Yasutsugu Takada and Noriaki Tanaka and Satoshi Teraoka and Morito Monden",
year = "2012",
month = "11",
day = "1",
doi = "10.1111/j.1399-0012.2012.01627.x",
language = "English",
volume = "26",
pages = "857--867",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Steroid-free living donor liver transplantation for HCV - a multicenter prospective cohort study in Japan

AU - Marubashi, Shigeru

AU - Umeshita, Koji

AU - Asahara, Toshimasa

AU - Fujiwara, Kenji

AU - Haga, Hironori

AU - Hashimoto, Takashi

AU - Hatakeyama, Katsuyoshi

AU - Ichida, Takafumi

AU - Kanematsu, Takashi

AU - Kitajima, Masaki

AU - Kiyosawa, Kendo

AU - Makuuchi, Masatoshi

AU - Miyagawa, Shinichi

AU - Satomi, Susumu

AU - Soejima, Yuji

AU - Takada, Yasutsugu

AU - Tanaka, Noriaki

AU - Teraoka, Satoshi

AU - Monden, Morito

PY - 2012/11/1

Y1 - 2012/11/1

N2 - This prospective, non-randomized, multicenter cohort study analyzed the safety and efficacy of a steroid-free immunosuppressive (IS) protocol for hepatitis C virus (HCV)-positive living donor liver transplant (LDLT) recipients in Japan. Of 68 patients enrolled from 13 transplant centers, 56 fulfilled the inclusion/exclusion criteria; 27 were assigned the steroid-free IS protocol (Fr group) and 29 the traditional steroid-containing IS protocol (St group). Serum HCV RNA levels increased over time and were higher in the St group until postoperative day 90 (POD 14, p = 0.013). Preemptive anti-HCV therapy was started in a higher percentage of recipients (59.3%) in the Fr group than in the St group (31.0%, p = 0.031), mainly due to early HCV recurrence. The incidence of HCV recurrence at one yr was lower in the Fr group (22.2%) than in the St group (41.4%; p = 0.066). The incidence of acute cellular rejection was similar between groups. New onset diabetes after transplant, cytomegalovirus infection, and renal dysfunction were significantly less frequent in the Fr group than in the St group (p = 0.022, p < 0.0001, p = 0.012, respectively). The steroid-free IS protocol safely reduced postoperative morbidity and effectively suppressed both the HCV viral load in the early post-transplant period and HCV recurrence in HCV-positive LDLT recipients.

AB - This prospective, non-randomized, multicenter cohort study analyzed the safety and efficacy of a steroid-free immunosuppressive (IS) protocol for hepatitis C virus (HCV)-positive living donor liver transplant (LDLT) recipients in Japan. Of 68 patients enrolled from 13 transplant centers, 56 fulfilled the inclusion/exclusion criteria; 27 were assigned the steroid-free IS protocol (Fr group) and 29 the traditional steroid-containing IS protocol (St group). Serum HCV RNA levels increased over time and were higher in the St group until postoperative day 90 (POD 14, p = 0.013). Preemptive anti-HCV therapy was started in a higher percentage of recipients (59.3%) in the Fr group than in the St group (31.0%, p = 0.031), mainly due to early HCV recurrence. The incidence of HCV recurrence at one yr was lower in the Fr group (22.2%) than in the St group (41.4%; p = 0.066). The incidence of acute cellular rejection was similar between groups. New onset diabetes after transplant, cytomegalovirus infection, and renal dysfunction were significantly less frequent in the Fr group than in the St group (p = 0.022, p < 0.0001, p = 0.012, respectively). The steroid-free IS protocol safely reduced postoperative morbidity and effectively suppressed both the HCV viral load in the early post-transplant period and HCV recurrence in HCV-positive LDLT recipients.

UR - http://www.scopus.com/inward/record.url?scp=84870705403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870705403&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2012.01627.x

DO - 10.1111/j.1399-0012.2012.01627.x

M3 - Article

C2 - 22507465

AN - SCOPUS:84870705403

VL - 26

SP - 857

EP - 867

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 6

ER -